Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices

TY - JOUR

T1 - Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices

AU - Fried, Justin

AU - Levin, Allison P.

AU - Mody, Kanika M.

AU - Garan, Arthur R.

AU - Yuzefpolsakaya, Melana

AU - Takayama, Hiroo

AU - Diuguid, David L.

AU - Naka, Yoshifumi

AU - Jorde, Ulrich

AU - Uriel, Nir

N1 - Publisher Copyright: © 2014 International Society for Heart and Lung Transplantation. All rights reserved.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: Mechanical support leads to an increased risk of both bleeding and thrombotic events, but little is known about the risk of device support in patients with a baseline predisposition to these events. The aim of this study was to examine outcomes among patients with baseline hematologic conditions who underwent continuous-flow LVAD implantation (CF-LVAD).Methods: We retrospectively reviewed records of 286 patients who underwent CF-LVAD implantation at the Columbia University Medical Center between April 2008 and December 2013. Patients diagnosed with the following hematologic conditions were enrolled: idiopathic thrombocytopenic purpura (ITP); Factor V Leiden; elevated Factor VIII; heparin-induced thrombocytopenia (HIT); or undefined hypercoagulable state.Conclusions: Patients with a history of prior hematologic conditions are at high risk for bleeding, thrombotic and neurologic events during device support, leading to early mortality. This case series questions the benefit of CF-LVAD in these patients and the appropriate management with regard to anti- coagulation. Further studies on the outcomes of these patients are warranted.Results: Of the 286 CF-LVAD patients implanted during the study period, 12 were considered to have a significant hematologic condition predisposing them to either bleeding or thrombotic events. The study included 5 patients with ITP, 1 with Factor V Leiden, 1 with elevated Factor VIII, 2 with HIT and 3 patients with undefined hypercoagulable state. Patients were supported for a total of 168.46 months, with a median of 10.76 months (IQR 4.78 to 21.36 months). There was a high frequency of thrombotic (0.57 event per patient-year), neurologic (0.36 event per patient-year) and bleeding (0.64 event per patient-year). Actuarial survival rates at 6 and 12 months were 81.8%, but fell to 49% at 2 years.

AB - Background: Mechanical support leads to an increased risk of both bleeding and thrombotic events, but little is known about the risk of device support in patients with a baseline predisposition to these events. The aim of this study was to examine outcomes among patients with baseline hematologic conditions who underwent continuous-flow LVAD implantation (CF-LVAD).Methods: We retrospectively reviewed records of 286 patients who underwent CF-LVAD implantation at the Columbia University Medical Center between April 2008 and December 2013. Patients diagnosed with the following hematologic conditions were enrolled: idiopathic thrombocytopenic purpura (ITP); Factor V Leiden; elevated Factor VIII; heparin-induced thrombocytopenia (HIT); or undefined hypercoagulable state.Conclusions: Patients with a history of prior hematologic conditions are at high risk for bleeding, thrombotic and neurologic events during device support, leading to early mortality. This case series questions the benefit of CF-LVAD in these patients and the appropriate management with regard to anti- coagulation. Further studies on the outcomes of these patients are warranted.Results: Of the 286 CF-LVAD patients implanted during the study period, 12 were considered to have a significant hematologic condition predisposing them to either bleeding or thrombotic events. The study included 5 patients with ITP, 1 with Factor V Leiden, 1 with elevated Factor VIII, 2 with HIT and 3 patients with undefined hypercoagulable state. Patients were supported for a total of 168.46 months, with a median of 10.76 months (IQR 4.78 to 21.36 months). There was a high frequency of thrombotic (0.57 event per patient-year), neurologic (0.36 event per patient-year) and bleeding (0.64 event per patient-year). Actuarial survival rates at 6 and 12 months were 81.8%, but fell to 49% at 2 years.

KW - ITP

KW - LVAD

KW - bleeding

KW - hematological conditions

KW - hypercoagulable

KW - mechanical circulatory support

KW - patient selection

KW - thrombosis

UR - https://www.scopus.com/pages/publications/84908017020

U2 - 10.1016/j.healun.2014.07.002

DO - 10.1016/j.healun.2014.07.002

M3 - Article

C2 - 25085498

SN - 1053-2498

VL - 33

SP - 1119

EP - 1125

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

IS - 11

ER -